Clinical-stage biotechnology company GlycoMimetics has completed patient enrollment for the Phase 2 sickle cell disease study evaluating GMI-1070.
Hospitalized sickle cell disease patients experiencing vaso-occlusive crisis were examined for the efficacy, safety and pharmacokinetics of GMI-1070.
The double-blinded study enrolled a total of 76 patients between 12 to 65 years of age at 22 clinical trial sites across US and Canada.
GlycoMimetics chief medical officer and clinical development vice president Helen Thackray said, “Evaluating GMI-1070 in the treatment of individuals with sickle cell who have been hospitalized with vaso-occlusive crisis represents a critical next step towards potentially fulfilling an important medical need in this historically underserved patient population.”
Topline results from the randomized study are expected in the second quarter of 2013.
